Literature DB >> 26924349

Determinants of mortality and impact of therapy in patients with leptospirosis admitted for intensive care in a Sri Lankan hospital--a three year retrospective study.

P N Weeratunga1, S Fernando, S Sriharan, M Gunawardena, S Wijenayake.   

Abstract

INTRODUCTION: Leptospirosis is a disease of epidemic proportions in Sri Lanka. There is paucity of data on the determinants of mortality and impact of therapy in patients with leptospirosis admitted to critical care settings in endemic territories.
METHODOLOGY: This retrospective cross-sectional study was performed in patients with serologically confirmed leptospirosis admitted to the intensive care unit of the General Hospital, Kalutara from January 2011 to April 2014. Associations between socio-epidemiological, clinical and laboratory parameters and patient mortality were examined.
RESULTS: Forty-five patients were included. The mean age was 49.11(SD = 16.95) and majority (92%) were male. Percentage mortality was 44.4%. Patient mortality was associated with age > 40 (p = 0.012), symptoms of uremia (p = 0.017), evidence of CNS involvement (p = 0.039), presence of oliguria (p = 0.002) and anuria (p = 0.014), presence of multi-organ dysfunction syndrome (MODS) (p < 0.001), CRP > 96 (p = 0.036), platelet count < 20,000 (p = 0.045), Potassium > 5.0 (p = 0.05), metabolic acidosis with pH < 7.2 (p = 0.03), INR > 2 (p = 0.037) and requirement of mechanical ventilation (p < 0.001). Cox regression analysis revealed MODS and potassium > 5 to be independently associated with mortality.
CONCLUSIONS: A high mortality rate is noted. The presence of MODS and serum potassium concentration > 5.0 was independently associated with mortality in this retrospective study of patients with confirmed leptospirosis in a critical care setting.

Entities:  

Keywords:  Intensive care; Leptospirosis; Mortality

Mesh:

Substances:

Year:  2015        PMID: 26924349      PMCID: PMC4809234          DOI: 10.1080/20477724.2015.1126032

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  41 in total

1.  Prognostic factors associated with severe leptospirosis.

Authors:  B Doudier; S Garcia; V Quennee; P Jarno; P Brouqui
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

Review 2.  Pathology and pathophysiology of pulmonary manifestations in leptospirosis.

Authors:  Marisa Dolhnikoff; Thais Mauad; Eduardo P Bethlem; Carlos Roberto Ribeiro Carvalho
Journal:  Braz J Infect Dis       Date:  2007-02       Impact factor: 1.949

3.  Pulmonary leptospirosis: an excellent response to bolus methylprednisolone.

Authors:  V V Shenoy; V S Nagar; A A Chowdhury; P S Bhalgat; N I Juvale
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

4.  Predictors of mortality in leptospirosis: an observational study from two hospitals in Kolkata, eastern India.

Authors:  Rudra P Goswami; Rama P Goswami; Ayan Basu; Santanu Kumar Tripathi; Sanghamitra Chakrabarti; Indrajit Chattopadhyay
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-10-30       Impact factor: 2.184

5.  Prognostic factors of death in leptospirosis: a prospective cohort study in Khon Kaen, Thailand.

Authors:  Thanachai Panaphut; Somnuek Domrongkitchaiporn; Bandit Thinkamrop
Journal:  Int J Infect Dis       Date:  2002-03       Impact factor: 3.623

6.  Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality.

Authors:  J F P Wagenaar; M G A Goris; D L Partiningrum; B Isbandrio; R A Hartskeerl; D P M Brandjes; J C M Meijers; M H Gasem; E C M van Gorp
Journal:  Trop Med Int Health       Date:  2009-12-09       Impact factor: 2.622

Review 7.  Leptospirosis: an emerging global public health problem.

Authors:  P Vijayachari; A P Sugunan; A N Shriram
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

8.  Door-to-dialysis time and daily hemodialysis in patients with leptospirosis: impact on mortality.

Authors:  Lúcia Andrade; Sérgio Cleto; Antonio C Seguro
Journal:  Clin J Am Soc Nephrol       Date:  2007-06-20       Impact factor: 8.237

9.  Clinical profile of leptospirosis in South gujarat.

Authors:  A M Clerke; A C Leuva; C Joshi; S V Trivedi
Journal:  J Postgrad Med       Date:  2002 Apr-Jun       Impact factor: 1.476

10.  Pulmonary involvement and leptospirosis, Greece.

Authors:  Anna Papa; Dionysia Theoharidou; Antonis Antoniadis
Journal:  Emerg Infect Dis       Date:  2009-05       Impact factor: 6.883

View more
  6 in total

1.  The Applicability of Commonly Used Severity of Illness Scores to Tropical Infections in Australia.

Authors:  Kris Salaveria; Simon Smith; Yu-Hsuan Liu; Richard Bagshaw; Markus Ott; Alexandra Stewart; Matthew Law; Angus Carter; Josh Hanson
Journal:  Am J Trop Med Hyg       Date:  2021-10-18       Impact factor: 3.707

2.  Leptospirosis presenting as severe cardiogenic shock: A case report.

Authors:  E Forbat; M J Rouhani; C Pavitt; S Patel; R Handslip; S Ledot
Journal:  J Intensive Care Soc       Date:  2018-01-29

3.  Estimating the burden of leptospirosis in Sri Lanka; a systematic review.

Authors:  Janith Warnasekara; Iresha Koralegedara; Suneth Agampodi
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.090

4.  Determinants of prolonged hospitalization and mortality among leptospirosis patients attending tertiary care hospitals in northeastern state in peninsular Malaysia: A cross sectional retrospective analysis.

Authors:  Yassin K Al Hariri; Syed A S Sulaiman; Amer H Khan; Azreen S Adnan; Sundos Q Al-Ebrahem
Journal:  Front Med (Lausanne)       Date:  2022-09-09

5.  Circulating microtranscriptome profiles reveal distinct expression of microRNAs in severe leptospirosis.

Authors:  Umaporn Limothai; Janejira Dinhuzen; Titipon Payongsri; Sasipha Tachaboon; Pisit Tangkijvanich; Natthaya Chuaypen; Nattachai Srisawat
Journal:  PLoS Negl Trop Dis       Date:  2020-11-11

6.  Leptospirosis in Intensive Care Unit.

Authors:  Niteen D Karnik; Aditi S Patankar
Journal:  Indian J Crit Care Med       Date:  2021-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.